These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
925 related articles for article (PubMed ID: 32859638)
21. Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC. Kim Y; Lee B; Shim JH; Lee SH; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K J Thorac Oncol; 2019 Feb; 14(2):193-202. PubMed ID: 30391576 [TBL] [Abstract][Full Text] [Related]
22. Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer. Hu W; Liu Y; Chen J Oncotarget; 2017 Apr; 8(15):25046-25054. PubMed ID: 28212572 [TBL] [Abstract][Full Text] [Related]
23. Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer. Chen M; Xu Y; Zhao J; Zhong W; Zhang L; Bi Y; Wang M EBioMedicine; 2019 Apr; 42():304-310. PubMed ID: 30878600 [TBL] [Abstract][Full Text] [Related]
24. Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study. Pilotto S; Rossi A; Vavalà T; Follador A; Tiseo M; Galetta D; Morabito A; Di Maio M; Martelli O; Caffo O; Piovano PL; Cortinovis D; Zilembo N; Casartelli C; Banna GL; Ardizzoia A; Barzelloni ML; Bearz A; Genestreti G; Mucciarini C; Filipazzi V; Menis J; Rizzo E; Barbieri F; Rijavec E; Cecere F; Spitaleri G; Bria E; Novello S Clin Lung Cancer; 2018 Jan; 19(1):93-104. PubMed ID: 28645631 [TBL] [Abstract][Full Text] [Related]
25. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases. Yu X; Sheng J; Pan G; Fan Y Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485 [TBL] [Abstract][Full Text] [Related]
26. Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non-Small Cell Lung Cancer with PIK3CA/PTEN Alterations. Grazini U; Markovets A; Ireland L; O'Neill D; Phillips B; Xu M; Pfeifer M; Vaclova T; Martin MJ; Bigot L; Friboulet L; Hartmaier R; Cuomo ME; Barry ST; Smith PD; Floc'h N Clin Cancer Res; 2024 Sep; 30(18):4143-4154. PubMed ID: 38630555 [TBL] [Abstract][Full Text] [Related]
27. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations. Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986 [TBL] [Abstract][Full Text] [Related]
28. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Gelatti ACZ; Drilon A; Santini FC Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888 [TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs). Martínez-Navarro EM; Rebollo J; González-Manzano R; Sureda M; Evgenyeva E; Valenzuela B; Fernández FJ; Forteza J; Brugarolas A Clin Transl Oncol; 2011 Nov; 13(11):812-8. PubMed ID: 22082647 [TBL] [Abstract][Full Text] [Related]
30. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study. Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564 [TBL] [Abstract][Full Text] [Related]
31. Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial. Zhang YC; Chen ZH; Zhang XC; Xu CR; Yan HH; Xie Z; Chuai SK; Ye JY; Han-Zhang H; Zhang Z; Bai XY; Su J; Gan B; Yang JJ; Li WF; Tang W; Luo FR; Xu X; Wu YL; Zhou Q EBioMedicine; 2019 May; 43():180-187. PubMed ID: 31027916 [TBL] [Abstract][Full Text] [Related]
32. Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population. Aguiar F; Fernandes G; Queiroga H; Machado JC; Cirnes L; Souto Moura C; Hespanhol V Arch Bronconeumol (Engl Ed); 2018 Jan; 54(1):10-17. PubMed ID: 29079040 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis. Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745 [TBL] [Abstract][Full Text] [Related]
34. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Kanda S; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Kubota K; Tamura T; Ohe Y Lung Cancer; 2015 Sep; 89(3):287-93. PubMed ID: 26169499 [TBL] [Abstract][Full Text] [Related]
35. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437 [TBL] [Abstract][Full Text] [Related]
36. Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA. Otsubo K; Sakai K; Takeshita M; Harada D; Azuma K; Ota K; Akamatsu H; Goto K; Horiike A; Kurata T; Nakagaki N; Nosaki K; Iwama E; Nakanishi Y; Nishio K; Okamoto I Oncologist; 2019 Aug; 24(8):1022-1026. PubMed ID: 31023862 [TBL] [Abstract][Full Text] [Related]
38. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations. Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086 [TBL] [Abstract][Full Text] [Related]
39. PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors. Ferrara MG; Martini M; D'Argento E; Forcella C; Vita E; Di Noia V; Sperduti I; Bilotta M; Ribelli M; Damiano P; Cannella A; Stefani A; Pilotto S; Carbone C; Piro G; Milella M; Tortora G; Bria E Clin Lung Cancer; 2021 Jul; 22(4):351-360. PubMed ID: 33558194 [TBL] [Abstract][Full Text] [Related]
40. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]